Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... OF ELAGOLIX ON BONE MINERAL DENSITY, SAN DIEGO, ... announced today that the elagolix 0603 Phase IIb trial,(Petal ... subject,completed her Week 24 study visit in early June. ... on bone mineral density (BMD) as,the primary endpoint using ...
... Prevention and Control Professionals Cite,Greatest Needs for ... More Environmental Services and Time-Saving High Tech ... than three out of four,(76%) infection prevention ... implemented additional measures to prevent the,transmission of ...
Cached Medicine Technology:Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 2Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis 3Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3
(Date:9/18/2014)... German . ... the ,International Space Station Research Competition, with their project ... scientists will see the International Space Station crew perform ... two proteins of the hepatitis C virus under microgravity ... Space Station is scheduled to lift off from Cape ...
(Date:9/18/2014)... 2014 According to a new market report ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 77607.7 million in 2013 and is ... to 2020, to reach an estimated value of USD 115474.9 ... market is growing at a rapid pace due to increasing ...
(Date:9/18/2014)... September 18, 2014 “Awesome” is the ... (Smart Teens Accepting Responsibility Today) Internship Program at ARDX ... Darcy C. describe the program as “Inspirational” and “Life-changing,” ... idea about what they would be doing during their ... do food runs and other mindless tasks,” but, instead ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, ... may be associated with increased odds of developing Parkinson,s ... research suggests. The study, which did not prove ... suggested that the migraine-Parkinson,s association was stronger in women ... warning sign of a pending attack that includes flashes ...
(Date:9/18/2014)... 2014 How much is a serving? ... the factors contributing to the obesity epidemic in the ... serving and how to manage portion size during the ... 3 at Humility House, 755 Ohltown Road, Austintown. , ... the informational discussion and answer questions from 12:30 to ...
Breaking Medicine News(10 mins):Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:HMHP Workshop Addresses Portion Control 2
... and poultry products from Taiwan, Hong Kong, and four ... to 17.//,The step has come as a precaution against ... ,Last month, Pakistan put a similar ban on ... Indonesia, Cambodia, Laos, Russia, Kazakhstan, Mongolia, Turkey, Greece and ...
... is a major factor increasing the cholesterol level in ... by the body in moderate amounts, can lead to ... Lena Brydon of University College London examined 199 healthy ... to stress and whether their reaction can increase cholesterol ...
... bird flu, even as the government has given approval to ... ,The latest outbreaks of the deadly H5N1 strain of the ... province of Yunnan and the northwestern region of Ningxia, the ... died in Yunnan's Chuxiong district Thursday, and 230 died in ...
... of its super-speciality hospital chain with a 280-bed hospital ... ,"We have embarked on the construction of a ... be ready by 2007-end. We also plan Greenfield projects ... president, told IANS., ,Unlike the existing 110-bed cardiac ...
... of more than 1,200 children, whose organs were removed after ... an average of about ?2,900 in a compensation deal announced ... is the apex body had fought the cases involving ... ago to a total figure of around ?3.6 million for ...
... could be putting their health at risk by failing ... other health professionals.// ,The survey of more than ... Professions Council (HPC), found that about 81% of people ... were oblivious to whether they were properly qualified to ...
Cached Medicine News:Health News:Wockhardt Group Plans Hospital In Delhi By End-2007 2Health News:Organ Scandals Compensation And The Aftermath 2Health News:Credentials Of Specialists Need To Be Checked 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: